MX2011007557A - Formas nuevas de bendamustina como base libre. - Google Patents

Formas nuevas de bendamustina como base libre.

Info

Publication number
MX2011007557A
MX2011007557A MX2011007557A MX2011007557A MX2011007557A MX 2011007557 A MX2011007557 A MX 2011007557A MX 2011007557 A MX2011007557 A MX 2011007557A MX 2011007557 A MX2011007557 A MX 2011007557A MX 2011007557 A MX2011007557 A MX 2011007557A
Authority
MX
Mexico
Prior art keywords
free base
bendamustine free
forms
novel forms
bendamustine
Prior art date
Application number
MX2011007557A
Other languages
English (en)
Spanish (es)
Inventor
Laurent D Courvoisier
Mark Eddleston
Curtis R Haltiwanger
Robert E Mckean
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42008533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011007557(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MX2011007557A publication Critical patent/MX2011007557A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
MX2011007557A 2009-01-15 2010-01-14 Formas nuevas de bendamustina como base libre. MX2011007557A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14484309P 2009-01-15 2009-01-15
PCT/US2010/020992 WO2010083276A1 (en) 2009-01-15 2010-01-14 Novel forms of bendamustine free base

Publications (1)

Publication Number Publication Date
MX2011007557A true MX2011007557A (es) 2011-08-12

Family

ID=42008533

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007557A MX2011007557A (es) 2009-01-15 2010-01-14 Formas nuevas de bendamustina como base libre.

Country Status (16)

Country Link
US (1) US8076366B2 (https=)
EP (1) EP2387400A1 (https=)
JP (1) JP2012515210A (https=)
KR (1) KR20110110293A (https=)
CN (2) CN102281877B (https=)
AU (2) AU2010204765A1 (https=)
BR (1) BRPI1004922A2 (https=)
CA (1) CA2749101A1 (https=)
EA (1) EA020767B1 (https=)
IL (1) IL213725A0 (https=)
MX (1) MX2011007557A (https=)
NZ (1) NZ594010A (https=)
SG (1) SG172810A1 (https=)
UA (1) UA109109C2 (https=)
WO (1) WO2010083276A1 (https=)
ZA (1) ZA201105099B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2516404A4 (en) * 2009-12-23 2013-04-17 Reddys Lab Ltd Dr PREPARATION OF BENDAMUSTINE AND ITS SALTS
SMT201700043T1 (it) 2010-01-28 2017-03-08 Eagle Pharmaceuticals Inc Formulazioni di bendamustina
EP2720547A4 (en) * 2011-06-20 2014-11-05 Hetero Research Foundation PROCESS FOR BENDAMUSTINE HYDROCHLORIDE
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
CN104271135B (zh) 2012-03-20 2017-05-17 赛多斯有限责任公司 在要求减少施用容量的患者中治疗苯达莫司汀响应性状况的方法
JP6250628B2 (ja) 2012-03-20 2017-12-20 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチンの製剤
ES2670995T3 (es) 2013-03-12 2018-06-04 Cephalon, Inc. Formulaciones de nanopartículas y macropartículas
EP4218543A1 (en) 2013-04-26 2023-08-02 Genentech, Inc. Contour integration perimetry vision test
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE80967C (https=)
DE293808C (https=)
DE159877C (https=)
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DD159877A1 (de) * 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
DK0752248T3 (da) * 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
DK0725642T3 (da) * 1993-10-27 2000-05-29 Upjohn Co Stabiliseret prostaglandin E1
US5561121A (en) 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
WO2000002555A1 (en) * 1998-07-09 2000-01-20 Nardella Francis A Methods and compositions for the treatment of chronic lymphocytic leukemia
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
DE10016077A1 (de) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
PL362979A1 (en) * 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
CN1487936A (zh) * 2000-12-11 2004-04-07 ����ҩƷ��ҵ��ʽ���� 具有改进吸收性能的药物组合物
CN1568166A (zh) * 2001-10-15 2005-01-19 荷姆泰克股份有限公司 预防再狭窄的涂层支架
US6613927B1 (en) * 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
AU2003221517B2 (en) 2002-03-22 2010-02-18 Christian Straka Cytocapacity test
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1495124A2 (en) 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1501565B1 (de) 2002-05-09 2006-11-02 Hemoteq GmbH Verbindungen und verfahren zur hemokompatiblen beschichtung von oberflächen
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
CA2516191A1 (en) * 2003-02-14 2004-09-02 Salmedix, Inc Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
KR20060052880A (ko) * 2003-07-25 2006-05-19 와이어쓰 동결건조된 ｃｃｉ- 779 제형
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
MX2011003751A (es) * 2008-10-08 2011-04-27 Cephalon Inc Procesos para preparar bendamustina.

Also Published As

Publication number Publication date
BRPI1004922A2 (pt) 2019-09-24
US20100210701A1 (en) 2010-08-19
EP2387400A1 (en) 2011-11-23
CN102281877B (zh) 2014-07-23
KR20110110293A (ko) 2011-10-06
UA109109C2 (uk) 2015-07-27
AU2016204902A1 (en) 2016-08-04
WO2010083276A1 (en) 2010-07-22
CN102281877A (zh) 2011-12-14
CN103554030A (zh) 2014-02-05
CA2749101A1 (en) 2010-07-22
SG172810A1 (en) 2011-08-29
NZ594010A (en) 2013-08-30
EA020767B1 (ru) 2015-01-30
EA201170934A1 (ru) 2011-12-30
IL213725A0 (en) 2011-07-31
US8076366B2 (en) 2011-12-13
AU2010204765A1 (en) 2011-07-28
ZA201105099B (en) 2012-03-28
JP2012515210A (ja) 2012-07-05

Similar Documents

Publication Publication Date Title
MX2011007557A (es) Formas nuevas de bendamustina como base libre.
MX342913B (es) Formas solidas de romidepsina y sus usos.
SI2247582T1 (sl) Brezvodna kristalinična oblika dimetoksi docetaksela in postopki za njihovo pripravo
HUE036085T2 (hu) Nagy tisztaságú és kristályos dimetil-fumarát elõállítására szolgáló eljárás
JO2887B1 (en) Spiro-pyridine compounds as ORL-1 receptor antagonists
IL206544A0 (en) Methods of preparing quinazolinone derivatives
MX2015003124A (es) Formas polimorficas de enzalutamida y su preparacion.
MX338327B (es) Inhibidores de cdk.
ZA201301992B (en) High toughness thermally stable polycrystalline diamond
AP3521A (en) Crystalline forms of hydrochloride salt of (4a-r,9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1h-indeno [2,1-b]pyridine-6-carbonitrile and their use as hsd 1 inhibitors
PH12012502252A1 (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
IL214421A0 (en) Methods for producing human amniotic cell lines
PH12015500733B1 (en) Method of weight management
IL221461A0 (en) Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same
WO2011104723A3 (en) Acid addition salts of ivabradine and preparation method thereof
MX343234B (es) Formas cristalinas de 6-(1h-imidazol-1-il)-2-fenilquinazolina.
IL215965A0 (en) Solvate crystals and methods of producing the same
ZA201202097B (en) Crystalline forms of substituted pyrazolopyrimidines
IL208918A0 (en) Methods of preparing substituted heterocycles-149
EP2349988A4 (en) ORGANIC NUTRIENT SALTS, PREPARATION METHODS AND USES THEREOF
GB0916195D0 (en) Surgical introducing tool kit
HUP0900130A3 (en) Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
HK1163514A (en) Novel forms of bendamustine free base
AU2009902649A0 (en) Methods of generating cells exhibiting phenotypic plasticity
TN2010000377A1 (en) Forms of rifaximin and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration